Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193167 · ClinicalTrials.gov registry record · Phase 2
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00193167 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 40 participants.
The verdict
NCT00193167, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
Interventions
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193167
The ClinicalTrials.gov registry entry for NCT00193167 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topotecan is the first listed.
NCT00193167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193167 about?
NCT00193167 is a clinical study titled "Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer". This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
What is the current status of trial NCT00193167?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00193167?
The interventions under investigation include: Topotecan (DRUG).
Who is sponsoring clinical trial NCT00193167?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.